Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 690517 in Healthy Japanese Male Subjects (Double-blind, Randomised, Placebo-controlled Within Dose Groups)
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2019
Price : $35 *
At a glance
- Drugs BI 690517 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 08 Feb 2019 Status changed from active, no longer recruiting to completed.
- 22 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Sep 2018 Planned End Date changed from 13 Dec 2018 to 31 Jan 2019.